Skip to content
Clinical Trials – home

Assistance Publique Hopitaux De Paris

Verified siteinfo

France 27 Rue Du Faubourg Saint Jacques, 75014 Paris, France

  • 29 trials recruiting
  • Endometrial cancer · Non-small cell lung cancer · Systemic scleroderma
  • Adults and children

About Specializations

Assistance Publique Hopitaux De Paris in Paris, France specialises in clinical trials of conditions such as Endometrial cancer, Non-small cell lung cancer, Systemic scleroderma, Ovarian cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms and Thoracic Oncology

At Assistance Publique Hopitaux De Paris, the clinical research portfolio is centered on cancer, with a strong focus on extensive stage small cell lung cancer. The trials in this area are designed to evaluate whether new treatment approaches can improve survival and disease control for patients with advanced lung malignancies.

  • Studies in small cell lung cancer are assessing whether adding new therapies can extend overall survival and strengthen first-line treatment options.
  • Research in thoracic oncology is focused on improving the effectiveness of care for patients with aggressive lung cancer.
  • The trials aim to test innovative immunotherapy-based strategies against standard treatment alone.

With 6 trials and 44 investigators, the Service Oncologie Thoracique is contributing to research that explores better ways to treat advanced neoplasms and improve outcomes for people with difficult-to-treat lung cancer.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
27 Rue Du Faubourg Saint Jacques75014 ParisFrance
Recruiting now
29 trials
Conditions studied
67
Partner status
Verified site

More sites in ParisFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

74 clinical trials

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

A Study Testing Anti-CD19 CAR T-Cell Therapy in Patients with Systemic Sclerosis Who Did Not Respond to Immunosuppressive Drugs

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Study on Bezafibrate for Patients with Primary Biliary Cholangitis Not Responding Well to Ursodeoxycholic Acid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Comparison of ruxolitinib versus hydroxycarbamide or interferon alfa as first treatment for high-risk polycythemia vera patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide
  • Sponsor:The University Of Birmingham

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Bronchiectasis

Recruiting

Study Comparing Ciprofloxacin, Colistimethate Sodium, and Ceftazidime for Treating Early Airway Infection in Adults with Bronchiectasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Neoplasm

Recruiting

Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Unicancer
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.